ClinicalTrials.gg
CompletedNCT03568539Updated Jun 1, 2021Results posted

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

A Phase 1 interventional study of IBI308 in Advanced/Metastatic Solid Malignancies, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-01.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies.

Patients will be recruited for 2 cohorts:

  • Cohort 1: Advanced/metastatic cancers with TMB>10 mutations per megabase (mut/Mb). This enrollment of this cohort has been stopped per sponsor's communication with the sites. For patients who have already enrolled in this cohort, treatment and monitoring will be conducted as stipulated by the protocol. The patients will remain on study until disease progression or intolerable toxicity, death, withdrawal of consent, or end of study, whichever occurs first.

Cohort 2: Advanced/metastatic endometrial cancer (N=40)

02

Conditions studied

  • Advanced/Metastatic Solid Malignancies

Keywords

  • Advanced/metastatic solid malignancies, TMB high
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects able to give voluntary , understand the study and are willing to follow and complete all the test procedures.
  2. Subjects (males and females) of should be willing to use reliable methods that are deemed effective by the investigator from visit 1 through 90 days following the last dose of study drug. women must have been amenorrhea for at least 12 months to be considered of non-childbearing potential.
  3. Male or female subjects ≥18 years

    1. At least one (per version 1.1)
    2. (ECOG) Performance Status ≤1.
    3. Subjects with of ≥ 3 month
  4. If subject received anti-tumor therapy:

    1. Generalized radiation therapy must have been completed 3 weeks prior to enrollment, or local radiotherapy or radiation therapy for bone for 2 weeks prior to enrollment. Treatment with radiopharmaceuticals must have been completed 8 weeks prior to enrollment.
    2. Previous chemotherapy, biotherapy (tumor vaccines, cytokines, or growth factors that control cancer), tyrosine kinase inhibitors, or approved targeting and other treatments should have completed at least 3 weeks prior to the first administered dose in this study;
  5. Subjects must have adequate organ function (liver, kidney function and hematopoietic function tests) prior IBI308 administration

    1. (ANC) ≥1.5 x10\^9/L
    2. count ≥ 100 x 10\^9/L
    3. ≥ 9 g / dL (whole blood or component transfusion within 7 days before 1st dose of study drug is prohibited)
    4. Renal function tests: serum creatinine ≤1.5 × (ULN) or an estimated (eGFR) ≥ 50 mL/min/1.73 m2
    5. Liver function tests (ALT) and aspartate aminotransferase (AST) ≤3 x ULN, for patients with known liver cancer or liver metastases, AST and ALT ≤ 5 x ULN
    6. Total (TBil) ≤1.5 x ULN; If Gilbert's Syndrome may have Bilirubin> 1.5 x ULN
    7. Coagulation tests: ≤ 1.5 x ULN and INR ≤2.0
  6. Cohort Specific Inclusion Criteria:

Cohort 1: Advanced/metastatic cancers with high TMB expression

i. Advanced/metastatic cancers with TMB level > 10 mut/Mb ii. or cytologically confirmed unresectable Stage III/IV NSCLC or other advanced/metastatic cancers (for example, melanoma, bladder cancer, SCLC, prostate cancer, colorectal cancer, gastric cancer) iiI. Separate informed consent is required for subjects who provide fresh for serial tumor biopsies for biomarker testing. TMB testing should be performed on the most recently obtained tumor sample.

v. Subjects must be tested for TMB level before entering the study, and pre-screen informed consent is required for TMB testing. Subjects who have existing FoundationOne TMB testing results from within 6 months of study entry do not need to have repeat testing.

vi. or intolerant to standard therapy or for whom no standard therapy exists. Subjects must have no available therapy likely to confer clinical benefit for their cancer. Subjects who experienced irAE grade ≥ 3, or grade 2 recurrent pneumonitis, or who had to discontinue prior /PD-L1 treatment due to irAEs of any grade will not be eligible.

vi. NSCLC subjects with EGFR mutation and/or ALK rearrangement and/or ROS-1 positive, should have received appropriate targeted therapy and are refractory to targeted therapy prior to enrolling this trial.

Cohort 2: Advanced/metastatic endometrial Cancer i. Histologically confirmed advanced/metastatic endometrial cancer. ii. Refractory or intolerant to standard therapy, and no available therapy likely to confer clinical benefit for their cancer. Subjects who experienced irAE grade ≥ 3, or who had to discontinue prior anti-PD-1/PD-L1 treatment due to irAEs of any grade will not be eligible.

Exclusion criteria

Exclusion Criteria:

  1. Legal incapacity or limited legal capacity.
  2. Pregnancy, lactation, breastfeeding.
  3. Concurrent anticancer treatment (e.g., cytoreductive therapy or cytokine therapy except for erythropoietin) or use of other product within 28 days before start of trial treatment; major surgery within 28 days before start of trial treatment (excluding prior diagnostic .

    Note: Small molecule or antibody targeted therapy \< 3 weeks from start of trial treatment will be excluded.

  4. Received a biologic (G-CSF, GM-CSF) within 14 days prior to the first dose of study drug.
  5. Vaccination within 4 weeks of first dose of IBI308 and while on study except for administration of inactivated vaccines (e.g., inactivated influenza vaccines)
  6. Failure to recover from adverse events from the most recent anti-tumor treatment to ≤ grade 1 or baseline with the exception of alopecia;
  7. Active disease requiring systemic treatment within the past 1 year or a documented history of clinically severe autoimmune disease or a syndrome that requires systemic or agents during the conduct of this study. Exceptions: - Vitiligo, eczema, psoriasis (\<10% of body surface area (BSA) of skin eruption or systemic involvement) or resolved childhood asthma/atopy, autoimmune hypothyroidism stable on hormone replacement.
  8. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  9. Acute or chronic , or (HIV) infection.
  10. History of primary immunodeficiency, stem cell or organ transplant, or previous clinical diagnosis of tuberculosis.
  11. Subject who have had severe infection within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose administration.
  12. Known allergies, , or intolerance to protein-based therapies or with a history of any significant drug allergy (e.g., anaphylaxis, hepatotoxicity, immune-mediated thrombocytopenia or anemia
  13. Subjects who experienced (irAE) grade≥3 immunotherapy-related adverse events. Subjects with unless they are asymptomatic or adequately treated with radiotherapy and/or surgery and subjects are neurologically stable with minimal residual symptoms/signs 14 days prior to dosing.
  14. Patients who require high dose of systemic corticosteroids (>10 mg/day prednisone or equivalents) for at least 2 weeks prior to treatment are not eligible.
  15. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure () NYHA III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 3 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
  16. Any other serious underlying medical (e.g., uncontrolled hypertension, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, other serious cardiac conditions not listed in exclusion criteria), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    IBI308

    Drug: IBI308

Interventions

  • DrugIBI308

    IBI308 200mg IV infusion, every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (Confirmed)

    To evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: 29 months

Secondary outcomes

  1. Progression-free Survival

    To measure progression-free survival rate (PFS) Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non- target lesion, or the appearance of new lesions

    Time frame: 2 years

  2. Duration of Response

    To measure duration of response (DOR)

    Time frame: 2 years

  3. Overall Survival

    To measure overall survival rate (OS)

    Time frame: 2 years

  4. Number of Participants With Detectable Anti- Drug Antibodies.

    Anti-Drug Antibodies will be tested to evaluate immunogenicity of IBI308

    Time frame: 2 years

  5. Area Under the Curve (AUC [0-504h])

    To evaluate the Area Under the Curve \[AUC\] of IBI308.

    Time frame: 0-504h

  6. Maximum Plasma Concentration [Cmax]

    To evaluate the Maximum Plasma Concentration \[Cmax\] of IBI308.

    Time frame: Cycle 1 Day 1: predose, 5 minutes, 1, 6, 24, 48, 168, and 336 hr post-end of infusion

07

Results

Posted Jun 1, 2021

Participant flow

Final analysis data cutoff date: Dec20. 39 subjects enrolled, 0 were ongoing.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started336
Completed336
Not completed00

Outcome measures

PrimaryOverall Response Rate (Confirmed)

To evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
29 months
Reported as:
Count of participants · Participants
Overall Response Rate (Confirmed)
ParticipantsCohort 1Cohort 2
Overall Response Rate (Confirmed)11
SecondaryProgression-free Survival

To measure progression-free survival rate (PFS) Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non- target lesion, or the appearance of new lesions

Time frame:
2 years
Reported as:
Median · Weeks
Progression-free Survival
WeeksCohort 1Cohort 2
Progression-free Survival17.14 (11.9 to 50.3)10.86 (5.7 to 12.0)
SecondaryDuration of Response

To measure duration of response (DOR)

Time frame:
2 years
Reported as:
Median · weeks
Duration of Response
weeksCohort 1Cohort 2
Duration of Response46.14 (46.14 to 46.14)15.29 (15.29 to 15.29)
SecondaryOverall Survival

To measure overall survival rate (OS)

Time frame:
2 years
Reported as:
Median · Week
Overall Survival
WeekCohort 1Cohort 2
Overall SurvivalNA (50.3 to NA)61.86 (61.86 to NA)
SecondaryNumber of Participants With Detectable Anti- Drug Antibodies.

Anti-Drug Antibodies will be tested to evaluate immunogenicity of IBI308

Time frame:
2 years
Reported as:
Count of participants · Participants
Number of Participants With Detectable Anti- Drug Antibodies.
ParticipantsCohort 1Cohort 2
Number of Participants With Detectable Anti- Drug Antibodies.01
SecondaryArea Under the Curve (AUC [0-504h])

To evaluate the Area Under the Curve \[AUC\] of IBI308.

Time frame:
0-504h
Reported as:
Geometric mean · hr*µg/mL
Area Under the Curve (AUC [0-504h])
hr*µg/mLCohort 1 & 2
Area Under the Curve (AUC [0-504h])10400 ± 34.4
SecondaryMaximum Plasma Concentration [Cmax]

To evaluate the Maximum Plasma Concentration \[Cmax\] of IBI308.

Time frame:
Cycle 1 Day 1: predose, 5 minutes, 1, 6, 24, 48, 168, and 336 hr post-end of infusion
Reported as:
Geometric mean · µg/mL
Maximum Plasma Concentration [Cmax]
µg/mLCohort 1 & 2
Maximum Plasma Concentration [Cmax]55.8 ± 18.5

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 11/3 (33.3%)2/3 (66.7%)3/3 (100%)
Cohort 218/36 (50%)12/36 (33.3%)34/36 (94.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventCohort 1Cohort 2
HypoxiaGastrointestinal disorders2/31/36
Lung infectionInfections and infestations1/30/36
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/30/36
ColitisGastrointestinal disorders1/30/36
NauseaGastrointestinal disorders1/30/36
HypotensionVascular disorders1/31/36
Cardiac failureCardiac disorders1/30/36
Cardiac failure congestiveCardiac disorders1/30/36
Urinary tract infectionInfections and infestations0/33/36
Pleural effusionRespiratory, thoracic and mediastinal disorders0/32/36
Most frequent other events
Showing 10 of 62
Most frequent other events
EventCohort 1Cohort 2
DiarrhoeaGastrointestinal disorders3/35/36
Oedema peripheralGeneral disorders2/36/36
HypotensionVascular disorders2/32/36
FatigueGeneral disorders1/315/36
NauseaGastrointestinal disorders1/38/36
Abdominal distensionGastrointestinal disorders1/34/36
ColitisGastrointestinal disorders1/30/36
Rectal haemorrhageGastrointestinal disorders1/30/36
PyrexiaGeneral disorders1/32/36
ChillsGeneral disorders1/31/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Total
<=18 years000
Between 18 and 65 years11415
>=65 years22224
Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Total
Median49.0 (44 to 78)67.5 (42 to 80)67.0 (42 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female23638
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino044
Not Hispanic or Latino33134
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native011
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American145
White22830
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Total
United States33639
08

Study locations

7 sites
  • UC Irvine Medical Center
    Orange, California 92868, United States
  • Northside Hospital, Inc
    Atlanta, Georgia 30342, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Nov 2020, 28 months.

Results were first posted in Jun 2021, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2018
First posted
Jun 26, 2018
StartActual
Jun 27, 2018
Primary completionActual
Nov 9, 2020
CompletionActual
Dec 7, 2020
Results first posted
Jun 1, 2021
Last update
Jun 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03568539
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Jun 27, 2018
Primary completion
Nov 9, 2020
Completion
Dec 7, 2020
Results posted
Jun 1, 2021
Last update
Jun 1, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion